Risks
4 risks
Risk Intelligence
Acute market weakness persists
View Risks →Alkem Laboratories Limited — Q2 FY25
Alkem's Q2 FY25 PAT grew 11% YoY to INR 6,886 million, driven by cost controls and a favorable product mix.
neutral
medium
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Alkem's Q2 FY25 PAT grew 11% YoY to INR 6,886 million, driven by cost controls and a favorable product mix. Domestic business lagged IPM growth due to acute market weakness and anti-infective underperformance, but management maintains 8-9% full-year domestic growth guidance. US business saw mid-single-digit erosion, with volume recovery (18.7% growth) offset by price erosion (6%). EBITDA margin guidance is 18.5-19% for FY25, a ~100bps improvement. Key risks include sustained acute market sluggishness and US pricing pressure. The enzyme plant commissioning is on track for Q4/Q1, and MedTech launch is expected in Q1 FY26.
अल्केम की दूसरी तिमाही में मुनाफा पिछले साल से 11% बढ़कर 688.6 करोड़ रुपये हो गया। इसकी वजह खर्चों पर काबू और सही उत्पाद मिश्रण है। भारतीय बाजार में कमजोरी और एंटी-इंफेक्टिव दवाओं की बिक्री घटने से कंपनी की ग्रोथ धीमी रही, फिर भी कंपनी को पूरे साल 8-9% ग्रोथ की उम्मीद है। अमेरिका में बिक्री थोड़ी घटी, क्योंकि कीमतें 6% गिरीं, लेकिन बिक्री की मात्रा 18.7% बढ़ी। कंपनी का EBITDA मार्जिन 18.5-19% रहने का अनुमान है। मुख्य जोखिम हैं: बाजार में सुस्ती और अमेरिका में कीमतों का दबाव। एंजाइम प्लांट चालू होने की तैयारी है और मेडटेक लॉन्च अगले साल की पहली तिमाही में होगा।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
US Volume Growth (Q2)
18.7%
+18.7pp YoY
US volume regrowth improved due to inventory normalization, recovering from supply chain issues.
US Price Erosion (Q2)
6%
-6pp YoY
Price erosion in US generic portfolio continues, impacting top line.
Domestic Volume Growth (Q2)
1.1%
+1.1pp YoY
Alkem outperformed industry volume growth of 0% in Q2.
Pan Brand Rank (MAT)
2nd in IPM
N/A
Pan became the second-largest brand in the Indian pharma market on a MAT basis.
What Changed vs Last Quarter
NEW
Domestic revenue growth of 8-9% for FY25
Management maintains full-year domestic growth guidance of 8-9%, with Q4 expected to be particularly strong.
NEW
EBITDA margin improvement of ~100bps to 18.5-19% for FY25
Full-year EBITDA margin expected to be 18.5-19%, driven by cost controls and product mix improvement.
NEW
US business flattish to mid-single-digit erosion for FY25
US revenue expected to decline flattish to mid-single-digit for the full year, with H2 performance better than H1.
NEW
Enzyme plant commissioning by Q4 FY25 or Q1 FY26
The US biologic CDMO plant is expected to begin production by Q4 FY25 or Q1 FY26, with break-even targeted in the first year.
DROPPED
Full-year EBITDA margin around 18%
Management expects EBITDA margin for FY25 to be around 18%, similar to last year, despite gross margin improvement, due to investments in new growth initiatives.
DROPPED
Gross margin improvement of ~150 bps to 62.5%
Full-year gross margin expected to improve to 62.5% from 61% in FY24, driven by favorable API pricing and product mix.
DROPPED
Domestic business growth in line with IPM (8-10%)
India business expected to grow in line with the Indian pharmaceutical market, which is projected at 8-10%.
DROPPED
US business single-digit growth with new launches
US business expected to see single-digit growth, with Dabigatran contributing meaningfully from Q3/Q4.
NEW RISK
Acute market weakness persists
The acute therapy market, especially anti-infectives, continues to show sluggish growth, impacting Alkem's high-acute portfolio.
NEW RISK
US pricing pressure and supply chain recovery
US business faces ongoing price erosion (6% in Q2) and the need to regain lost contracts after past supply issues.
NEW RISK
Exactech bankruptcy proceedings may affect MedTech launch
Partner Exactech is undergoing bankruptcy, which could disrupt technology transfer and launch timelines for the MedTech business.
NEW RISK
Market share loss in key anti-infective brands
Brands like Clavam and Xone have lost market share, partly due to increased competition from smaller players post-COVID.
RISK GONE
Product mix deterioration in acute season
Q2 and Q3 typically see higher anti-infective sales, which could lower margins by ~2% due to product mix shift.
RISK GONE
Investment drag from Enzene and medical devices
New initiatives (CDMO, medical devices) will incur losses and impact EBITDA by ~0.5 ppt in H2, with breakeven expected only by FY26.
RISK GONE
US price erosion and launch delays
US generic business faces single-digit price erosion; new product ramp-up may be slower than expected, limiting revenue contribution.
RISK GONE
Mirabegron launch uncertainty
Launch of Mirabegron is tied to litigation outcomes and settlement agreement, with earliest possible entry in 2026-27, limiting near-term US upside.
🤫 Topics management stopped discussing
Mentioned in Q2 FY24, Q4 FY24
Q4 had INR 30 crore in service-level penalties due to supply issues; if not resolved, could impact US margins.
Mentioned in Q2 FY24, Q3 FY24
Management expects FY24 EBITDA margin around 17%, with Q4 seasonally weaker but sustainable at that level.
Mentioned in Q1 FY25, Q2 FY24
Q2 and Q3 typically see higher anti-infective sales, which could lower margins by ~2% due to product mix shift.
Fast read
Guidance and risk preview
Management maintains full-year domestic growth guidance of 8-9%, with Q4 expected to be particularly strong.
The acute therapy market, especially anti-infectives, continues to show sluggish growth, impacting Alkem's high-acute portfolio.
View Risks →